About 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associated with Alzheimer's Disease. In a recent trial, in the group of patients with moderate to severe AD treated with memantine, there were fewer incidences of agitation. It is hypothesized that memantine will be effective in reducing the symptoms of agitation associated with moderate to severe Alzheimer's Disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
34
The Forves Norris MDA/ALS Research Center
San Francisco, California, United States
Coastal Communities Hospital
Westminster, California, United States
Alzheimer's Disease Research Unit
New Haven, Connecticut, United States
Neuropsychiatric Inventory
Cohen Mansfield Agitation Inventory
Clinical Global Impression Scale
ADCS-ADL
Agitation/aggression domain of Neuropsychiatric Inventory (NPI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Berma Research Group
Hialeah, Florida, United States
Baumel-Eisner Neuromedical Institute
Miami, Florida, United States
Premiere Research Institute
West Palm Beach, Florida, United States
Geriatric Medicine
Honolulu, Hawaii, United States
The Memory Clinic
Bennington, Vermont, United States
Hampton Roads Center for Clinical Research
Norfolk, Virginia, United States